BioSpace News Archive

A consortium of researchers led by Georgetown Lombardi Comprehensive Cancer Center investigators have completed the largest analysis of a new gene fusion they believe is responsible for development of a wide spectrum of cancer types.

Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2018.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, plans to release its first quarter 2019 results after the financial markets close on Tuesday, April 30, 2019.

The Kidney Cancer Association is pleased to announce its Board of Directors recently approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer.

Hatteras Venture Partners announced today the first closing of Hatteras Venture Partners VI, LP (HVP VI), with $94 million in deployable capital toward an ultimate target fund size of $200 million.

Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, presented in vivo proof of concept data for the DDS-04 series of new mechanism antibiotics targeting Enterobacteriaceae in an oral session at the 29th European Congress of Clinical Microbiology & Infectious Diseases (‘ECCMID’) in Amsterdam.

Calls out Suspicious Timing, Lack of Disclosure and Leadership as Confirmed by Negative Market Reaction

• The Australian launch of VivaGel® BV (Fleurstat BVgel) is the first launch globally with further launches to follow in Europe and other regions • Fleurstat BVgel (VivaGel® BV) is marketed in Australia by Aspen • VivaGel® BV is an Australian innovation – a non-antibiotic therapy – which addresses a global unmet medical need

Dr. Campion is a highly experienced biotech and pharmaceutical professional, bringing more than 20 years of experience in the industry.

Bernstein Liebhard LLP announced that only 6 weeks remain to make a motion for lead plaintiff in a securities class action lawsuit alleging claims on behalf of those who purchased the securities of American Renal Associates Holdings, Inc. between August 10, 2016 and March 27, 2019, both dates inclusive.